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Adoptive immunotherapy of patients with cancer using lymphoid cells expanded
from peripheral blood or directly from the autologous tumor has been extensively
investigated in our laboratory (1-6). Preliminary studies suggested the possible efficacy
of expanded tumor-infiltrating lymphocytes (TIL)' in the treatment of patients with
melanoma, in whom the existence of CTL specific for autologous tumors (2-5) and
the accumulation of transferred lymphocytes at the tumor site (6) have recently been
shown.
IL-4 is a species-specific pleiotropic lymphokine (7, 8) acting on various cell types,
including T cells, B cells, NK cells, and monocytes. High-affinity receptors for IL-4
have been detected on both hematopoietic and nonhematopoietic cells (7, 8). Human
IL-4 stimulates proliferation of T cells from peripheral blood and thymus with or
without other stimuli (9, 10). Preactivated T cell growth (9) and allo-specific CTL
generation (11, 12) are augmented by IL-4. It appears, however, that human IL-4
inhibits IL-2-induced lymphokine-activated killer (LAK) activity from unstimulated
cells (10-12). We demonstrate here that human IL-4 in conjunction with IL-2 aug-
ments the growth ofTIL apparently specific for autologous melanoma, and recipro-
cally inhibits nonspecific killer activity.
Materials and Methods
Lymphokines, Antibodies, and PhenotypicAnalysis.
￿
Human rIL-2 was kindly supplied by Cetus
Corp., Emeryville, CA. Human rIL-4 (108 U/mg in a tonsilar B cell growth assay with anti-
4 antibody) was generously provided by Dr. Steven Gillis (Immunex Corp., Seattle, WA).
FITC-conjugated anti-CD3 (Leu-4), CD4 (Leu-3), and CD8 (Leu-2) antibodies and
phycoerythrin (PE)-conjugated anti-NKHI (Leu-19) antibody were purchased from Becton
Dickinson & Co., Mountain View, CA. TIL were first incubated in heat-inactivated human
AB serum to block nonspecific binding. After a wash, cells were incubated with FITC- or
PE-conjugated mAbs for 1 h at 4°C. Cells were then washed and fixed with 1% paraformal-
dehyde for 10 min. Stained cells were analyzed using a FACS (model 440; Becton Dickinson
& Co.) and percent positive cells were determined.
TIL Culture.
￿
Tumor-mononuclear cell suspensions were prepared from 11 metastatic mela-
nomas resected from 10 patients as previously reported (13). Although vigorous attempts are
Address correspondence to Y. Kawakami, Surgery Branch, DCT, NCI, Bldg. 10, Rm. 2B51, National
Institutes of Health, Bethesda, MD 20892.
1 Abbreviations used in this paper: LAK, lymphokine-activated killer; PE, phycoerythrin; TIL, tumor-
infiltrating lymphocytes.
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made to remove tissues that do not clearly contain tumors, some of the cells derived in these
studies could be tumor- "associated" rather than tumor-infiltrating lymphocytes. Only pa-
tient 638 had previously received IL-2. Briefly, tumor specimens were minced into small pieces
and incubated for 2-16 h in RPMI 1640 (Biofluids, Rockville, MD) containing 0.01% hyaluroni-
dase type V, 0.002% DNAse type I, 0 .1% collagenase type IV (Sigma Chemical Co., St.
Louis, MO), 50 IU/ml penicillin, and 50 ug/ml streptomycin (Biofluids). Harvested cells were
centrifuged on lymphocyte separation media (Organon Tecknika Corp., Durham, NC). The
cells at the interface were collected, washed, resuspended in heat-inactivated human AB serum
(Advanced Biotechnologies, Inc., Silver Spring, MD), and frozen in the vapor phase of a
liquid N2 freezer. For TIL expansion, a total of 6 ml of either fresh or thawed cell suspen-
sions at a concentration of 10' cells/ml was cultured in 6-well plates (3506; Costar, Cam-
bridge, MA) in complete medium. This consisted of RPMI 1640 supplemented with 10%
heat-inactivated human AB serum, 2 mM L-glutamine (M. A. Bioproducts, Walkersville,
MD), 50 IU penicillin, and 50 ug/ml streptomycin, with or without IL-2 (10 or 1,000 U/ml)
or IL-4 (1,000 U/ml). During the initial culture, medium was changed one to three times
by replacement of three-quaters of supernatant with new medium containing the appropriate
concentration of lymphokines. During the subsequent maintenance culture, cells were har-
vested and adjusted to 2.5 x 105/ml in new media with lymphokines every 4-7 d. Irradiated
(5,000 rad) autologous tumor cells were added at 5 x 104/ml (TIL/Tumor ratio, 5 :1) in some
experiments, as noted.
Cytotoxicity Assay.
￿
Sequentially harvested cells from TIL cultures were used as effectors.
The B cell line, Daudi, as well as autologous fresh melanoma and two other fresh allogeneic
melanomas were used as targets. A 4-h "Cr release assay was performed as previously noted
(13). Briefly, targets were incubated with 200 gCi of Na"Cr04 for 1-1.5 h followed by washing
and filtering through nylon mesh. Various concentrations of effector cells at E/T ratios of
0.6-40 were mixed with 5 x 10' target cells in 96-well round-bottomed microplates (3799;
Costar) in triplicate, centrifuged for 5 min at 500 rpm, and then incubated for 4 h at 37°C
in a 5% C02 incubator. Supernatants were collected using a SkatronTitertek system (Ska-
tron, Inc., Norway) and counted on a gamma counter. Maximal or minimal lysis were mea-
sured using supernatants from wells receiving 2% SDS or media alone, respectively. Min-
imal lysis was usually <30% ofmaximal release. Percent specific lysis was calculated as: percent
specific lysis = 100 x (experimental release - minimal release)/(maximum release - min-
imal release). Cytotoxicity is expressed as LU per 10' cells. 1 LU is defined as the number
of effector cells mediating 20% specific lysis of 5 x 10' target cells, determined from the dose-
response curve previously described (2, 14). Total lytic activity was calculated by multiplying
LU/10' and fold expansion.
Statistical Analysis.
￿
Statistical analysis was performed using a two-tailed student's t test.
Results
Tumor-infiltrating Lymphocyte Expansion.
￿
Two phases ofculture are noted. The first,
or initiation phase, was the period during which lymphoid cells were first grown
from the tumor suspension. The second, or maintenance phase, denotes the period
during which these cells were further expanded in culture after all tumor cells had
been eliminated. The total time in culture (both initiation and maintenance phases)
are described as "overall culture." No lymphocytes expanded in cultures grown in
media or IL-4 (1,000 U/ml) alone for up to 30 d. In many cases, tumor cells grew
from these cultures. An experiment performed with tumors from patient 1 is shown
in detail in Fig. 1. A major advantage in terms of expansion as well as lytic activity
was observed. In the initial culture (6-29 d; median 18 d), IL-4 (1,000 U/ml) addi-
tion together with 10 or 1,000 U/ml IL-2 grew cells better than IL-2 alone in all
(11 :11) cases (Table I). Further, TIL recovery after culture with IL-2 (10 U/ml) and
IL-4 was better than that with IL-2 (1,000 U/ml) alone in most cases (7 :10) . During
the maintenance culture (7-29 d; median 17 d) IL-4 addition with IL-2 (10 U/ml)a
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FIGURE 1. IL-4 decreases
nonspecific killer activity, but
increases growth ofTIL capable
of killing autologous mela-
nomas. Cell expansionandper-
cent specific lysistested against
autologous melanoma and
Daudi at various E/T ratios of
TIL grownfrom apatientwith
IL-2,IL-4 (U/ml) on day 16 and
30 are shown. F. E., fold cell ex-
pansion.
grew TIL better than IL-2 (10 U/ml) alone, but less well than with IL-2 (1,000 U/ml)
alone. In contrast to the initial culture, TIL recovery with IL-2 (1,000 U/ml) and
IL-4 was less than that with IL-2 (1,000 U/ml) alone in some cases (4:10) (data not
shown). Finally, over the entire culture period ("overall;' 23-48 d; median 34 d), IL-
4 plus IL-2 grew TIL better than IL-2 alone in most cases (8:10). TIL did not grow
in three cases with IL-2 (10 U/ml) alone, in two cases with combinations of IL-2
(10 U/ml) and IL-4, and in one case with high levels ofIL-2 (1,000 U/ml). TIL grew
with IL-2 (1,000 U/ml) and IL-4 in all cases (11 :11) (Table I).
Weekly addition of 5,000 rad irradiated autologous tumor cells led to better TIL
expansion than cultures without tumor restimulation in most (4 :5) cases (Table II) .
With low-dose IL-2 (10 U/ml) alone, tumor addition sometimes appeared to inhibit
TIL growth. TILs maintained with IL-2 and IL-4 could subsequently grow when
transferred into mediacontaining IL-2 (10 U/ml) alone. The expansion under these
conditions was less than that observed with IL-2 (10 U/ml) and IL-4 in all cases (data
not shown).
Cytotoxic Activity and Specificity of TIL. TIL grown with IL-2 (10 U/ml) and IL-4
and tested after the initial culture (Table III) did not have significant nonspecific
LAK-like cytolytic activity against Daudi and two allogeneic melanoma targets in
most cases (7 :9). However, IL-4 with IL-2 (10 U/ml) usually augmented total lytic
activity observed against autologous melanoma (5 :7). IL-4 addition with IL-2 (1,0002186
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U/ml) decreased nonspecific cytolytic activity against Daudi or a number ofLAK-
sensitive allogeneic fresh melanomas (data not shown) compared with that in IL-2
alone in many cases (7:10 per cell and 6:10 on a per culture basis after the initial
culture; 3:5 per cell and 2:4 on a per culture basis after overall culture [data not
shown]). Reciprocally, IL-4addition increased the totallyticactivity against the au-
tologous melanoma in most cases (6:10 afterthe initial culture and 5:7 after overall
culture on a per culture basis [data not shown]).
Phenotype of Growing TIL.
￿
TIL grown IL-2 and/or IL-4 were mostly CD3+
(>80%) T cells and either CD8+ (9:11) or CD4' (2:11) predominant in most cases.
In one instance, IL-4 addition grew mainly CD4+ T cells, while CD3- Leu-19+
NK-like cells grew with IL-2 (1,000 u/ml) alone (data not shown). TIL 648 (day
40) grown with IL-2 and IL-4 was primarily CD4+ T cells. These cells prolifer-
ated best with an autologous tumor in the presence of50 U/ml ofIL-2, when mea-
sured by [3H]thymidine incorporation (data not shown) after 4 d of incubation.
Discussion
In murine models the transfer of 10-100-fold fewer tumor-specific T cells than
LAK cells is required for comparable antitumor effects in adoptive cellular im-
munotherapy experiments (15). Based on our murine studies, it is estimated that
>2 x 1011 TIL would be required to effectively treat patients bearing metastatic
cancer. Better methods to expand cells with specific antitumor activity are required.
IL-4 does stimulate T cell proliferation after allostimulation or with the mitogens,
PHA, Con A, orPMA (9, 10), and also augments the induction ofallospecific CTL
(11, 12). In contrast to murine studies (14), human IL-4 inhibits IL-2 induction of
LAK activity fromunstimulated lymphocytes ofvariouslymphoid organs by direct
inhibition of precursors to proliferate and differentiate into nonspecific killer cells
andto express IL-2-R (Tac). This could, in turn, suppress furtherproliferation (10-12,
Kawakami, Y., et al., submitted for publication). Since asialo-GM1+ LAK-like cells
seem to be responsible for the capillary leak syndrome in the mouse (16), it may
be reasonable to use human IL-4 for the selective growth oftumor-specific T cells
with IL-2 in vitro or in vivo. IL-4, together with IL-2, augmented T cell growth
and cytolysis against autologous melanomasbutdecreased nonspecific cytolysisagainst
Daudi or allogeneic melanomas. Some difference was observed from the previously
reported allospecific CTL, in that IL-4 alone can augment CTL inductionbutsimul-
taneous addition with IL-2 rather inhibits CTL generation as well as nonspecific
killer cells, obscuringinpart the specific response (11). IL-4mayaugmentTIL growth
by directlyacting on T cells as anadditive growth factor, byinducing Tcell subsets
thatcannot be grownwith IL-2 alone, byincreasingthe antigen-presenting function
ofmacrophages containedintumors (8), or alternatively, by inhibiting the suppres-
sive activity of tumors. Addition of irradiated tumor during culture led us to en-
hanced TIL expansion possibly because of restimulation of tumor-specific T cells
with putative tumor antigens.
IL-4 used with high-dose IL-2 sometimes decreased TIL growth during main-
tenance culture. IL-4 could be inhibitory to Tcell growth under certain conditions
by mechanisms that involve IL-4 inhibition ofIL-2 stimulated IL-2 R(Tac) expres-
sion. Accessory cells or factors such as IL-1 may be necessary to maintain Tcell
responsiveness to IL-4 as has been demonstrated with murine Th2 cells (17) and2190
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may be insufficient under our maintenance conditions. In our study, TIL main-
tained with IL-2 (10 U) and IL-4 expanded better in subsequent culture with low-
dose IL-2 (10 U) than TIL grown with IL-2 (1,000 U) and IL-4 (data not shown).
T cellsmaintained with such low doses of IL-2 in vitro may preferentially grow when
adoptively transferred to patients given IL-2 in whom attainable IL-2 levels are ex-
pected to be lower and possibly with less negative effects on the subsequent T cell
responsiveness to IL-2 (18).
Our data suggests that IL-4 selectively enhances the growth of T cells cytotoxic
to autologous melanomas with IL-2 . This strategy may be useful for expanding cells
with specific reactivity from inflammatory sites as well as other tumors.
Summary
Addition of IL-4 (1,000 U/ml) to either high or low concentrations of IL-2 aug-
mented tumor-infiltratinglymphocytes (TIL) growth from human melanoma. Weekly
restimulation with irradiated tumorcells in conjunction with IL-4 allowed enhanced
growth of TIL. With low-dose IL-2 (10 U/ml) and IL-4, expanded TIL had little
cytolytic activity against Daudi or allogeneic tumors. Further, IL-4 augmented the
total lytic activity against autologous tumors in most cases. With high-dose IL-2
(1,000 U/ml), IL-4 addition decreased nonspecific killing activity against Daudi or
allogeneic melanomas in many cases, and reciprocally augmented cytolytic activity
against the autologous melanoma in many cases. This suggests the possible use of
IL-4 in cancer therapy, especially in adoptive cellular immunotherapy using TIL
or in conjunction with IL-2 administration.
We thank Drs. James J. Mule and Hans St6tter for helpful discussions.
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